ethyl 3-[4-(2-bromoethoxy)phenyl]-2-phenoxypropanoate | 220747-01-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-[4-(2-bromoethoxy)phenyl]-2-phenoxypropanoate
• CAS: 220747-01-3
• 化学式: C₁₉H₂₁BrO₄
• 分子量: 393.277
• InChiKey: RZFXUWXNTPYXCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-[4-(2-bromoethoxy)phenyl]-2-phenoxypropanoate 在 potassium carbonate 作用下， 以85.4%的产率得到1-methyl-5-benzyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
  参考文献：
  名称：

  Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof

  摘要：

  本发明涉及新型抗肥胖和降胆固醇化合物，它们的衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。更具体地，本发明涉及一般式（I）的新型β-芳基-α-氧代烷基羧酸，其衍生物，类似物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。本发明还涉及制备上述新型化合物，其类似物，衍生物，互变异构体，立体异构体，多晶形态，药学上可接受的盐，药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物的方法。本发明还涉及新型中间体，其制备方法以及在制备式（I）化合物中的使用。

  公开号：

  US06444816B1

文献信息

• NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1073643B1

  公开（公告）日：2004-12-29
• ARYL SUBSTITUTED ALKYLCARBOXYLIC ACIDS AS HYPOCHOLESTEROLEMIC AGENTS
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1363914A1

  公开（公告）日：2003-11-26
• US6444816B1
  申请人：——

  公开号：US6444816B1

  公开（公告）日：2002-09-03
• [EN] NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES, LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：——

  公开号：WO1999008501A2

  公开（公告）日：1999-02-25

  [EN] The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel beta -aryl- alpha -oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
  [FR] L'invention concerne de nouveaux composés anti-obésité et hypocholestérolémiques, leurs dérivés, leurs analogues, leurs formes tautomères, leurs stéréoisomères, leurs polymorphes, leurs sels acceptables sur le plan pharmaceutique, leurs solvates acceptables sur le plan pharmaceutique et des compositions acceptables sur le plan pharmaceutique les contenant. Elle concerne, plus particulièrement, de nouveaux acides beta -aryl- alpha -oxysubstitué alkylcarboxyliques représentés par la formule (I), leurs dérivés, leurs analogues, leurs formes tautomères, leurs stéréoisomères, leurs polymorphes, leurs sels acceptables sur le plan pharmaceutique, leurs solvates acceptables sur le plan pharmaceutique et des compositions acceptables sur le plan pharmaceutique les contenant. (I)
• [EN] ARYL SUBSTITUTED ALKYLCARBOXYLIC ACIDS AS HYPOCHOLESTEROLEMIC AGENTS<br/>[FR] ACIDES ALKYLCARBOXYLIQUES SUBSTITUES PAR ARYLE UTILISES COMME AGENTS HYPOCHOLESTEROLEMIQUES
  申请人：REDDY RESEARCH FOUNDATION

  公开号：WO2002062799A1

  公开（公告）日：2002-08-15

  The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel b-aryl-a-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.